Pricing Log in Create free account
Saturday 17 October 2026 Export IRTC’s income statement to Excel — free account

iRhythm Holdings, Inc.

IRTC Healthcare Medical Devices

iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024. In the quarter to June 2026, revenue grew 20.1%, EPS grew 97.7%, free cash flow grew 117.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for ten consecutive years; insiders bought in the last twelve months.

108.66 0.69 −0.63%
Market cap
$3.6B
P/E
0.0×
Fwd P/E
−1,660×
Dividend yield
—
F-score
5/9
Altman Z
4.02
Beneish M
−3.04
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.06
Total sells 27.35
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — 1 — — — — —
Sell 2 2 — 11 9 — 1 2 2 8 1 —
Insider Ownership 1.90%

Capital & Financial Ratios $m

Market Cap 3,600.00
Revenue 825.34
Net Income (13.95)
Free Cash Flow 38.98
Net Debt 59.82
Current Ratio 3.86 (at or above 1.5: strong)
Debt/Equity 3.50 (above 2: weak)
P/E ratio 0.00
Fwd P/E (1,660.00) (negative: loss-making)
P/S ratio 4.33
P/B ratio 19.22 (above 6: high)
Past 5Y EPS Growth —
This Y EPS Growth 85.16% (at or above 15%: strong)
Next Y EPS Growth 662.86% (at or above 15%: strong)
Next Y revenue growth 19.26% (at or above 10%: strong)
Next 5Y EPS Growth 40.27% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.4×, against a ten-year median of 8.6×; over the ten years it ranged from 1.1× in 2016 to 26.8× in 2020.
P/S against its own 10 years 7.77%
10-year low 10-year high
P/B against its own 10 years 52.50%
10-year low 10-year high
EV/Sales against its own 10 years 8.76%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 134 536 584 591
Receivables 61 80 76 84
Inventory 14 14 22 23
Other — — — —
231 646 703 756
2023 2024 2025 Q'26
Payables 6 7 2 17
ST’ Debt — — — —
Other — — — —
107 111 152 196

Compound Annual Growth %

10y 5y 3y
Sales 35.38% 23.02% 22.05%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 0.00% (14.87%) (13.96%)

Revenue $m

Mar Jun Sep Dec Year
’26 199 224 — — —
’25 159 187 193 209 747
’24 132 148 148 164 592
’23 111 124 125 133 493
’22 92 102 104 113 411
’21 74 81 85 82 323
’20 64 51 72 79 265
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (26) 51 — — —
’25 (8) 28 35 26 81
’24 (52) 12 24 19 3
’23 (31) (5) 1 (16) (50)
’22 (39) 0 4 13 (23)
’21 (42) (1) 18 (13) (38)
’20 (22) (10) 11 8 (14)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (33) 38 — — —
’25 (17) 17 20 14 35
’24 (62) 3 1 12 (46)
’23 (39) (14) (8) (29) (91)
’22 (44) (11) (3) 5 (53)
’21 (46) (6) 4 (18) (66)
’20 (26) (12) 5 5 (27)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.43) (0.01) — — —
’25 (0.97) (0.44) (0.16) 0.17 (1.39)
’24 (1.47) (0.65) (1.48) (0.04) (3.63)
’23 (1.29) (0.61) (0.89) (1.26) (4.04)
’22 (1.71) (0.80) (0.71) (0.67) (3.88)
’21 (0.95) (0.59) (0.81) (1.10) (3.46)
’20 (0.34) (0.75) (0.17) (0.33) (1.58)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 22.16 28.70 55.18 56.24 56.54 41.66 88.73 70.24 55.92 86.55

Analyst estimates 2026–2028

Powerpack
High 31.69 57.91 98.37 98.13 274.21 286.19 169.54 140.23 124.12 212.00
People
People Employees 406 575 748 997 1,157 1,700 1,793 2,000 2,000 2,400
Revenue/emp, $m 0.16 0.17 0.20 0.22 0.23 0.19 0.23 0.25 0.30 0.31
Income, $m
Income, $m Revenue 64 99 147 215 265 323 411 493 592 747
Gross margin, % 67.41 71.55 73.66 75.54 73.50 66.16 68.54 67.35 68.86 70.57
EBT (21) (30) (50) (55) (44) (101) (116) (123) (113) (44)
EBT margin, % (32.62) (30.00) (34.18) (25.40) (16.44) (31.28) (28.20) (24.90) (19.05) (5.84)
Net income (21) (30) (50) (55) (44) (101) (116) (123) (113) (45)
Depreciation 1 2 2 3 7 11 19 17 27 26
Per share, $
Per share, $ Revenue 12.12 4.38 6.17 8.49 9.55 11.01 13.74 16.14 18.97 23.35
Earnings (3.95) (1.30) (2.02) (2.16) (1.58) (3.46) (3.88) (4.04) (3.63) (1.39)
Cash flow (3.15) (0.66) (1.22) (0.87) (0.50) (1.29) (0.77) (1.64) 0.11 2.53
Capex (0.52) (0.16) (0.22) (0.81) (0.49) (0.96) (1.00) (1.32) (1.57) (1.45)
Free cash flow (3.67) (0.82) (1.43) (1.67) (0.98) (2.24) (1.77) (2.97) (1.46) 1.08
Book value 17.51 3.52 2.18 5.36 12.31 9.53 8.02 6.88 2.91 4.77
Shares, m 5 23 24 25 28 29 30 31 31 32
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S 2.47 13.14 11.27 8.02 24.83 10.69 6.85 6.28 4.75 7.60
P/B 1.71 16.38 31.83 12.70 19.27 12.35 11.74 14.73 30.94 37.18
EV/Sales 1.32 12.45 10.98 7.53 23.69 10.02 6.44 6.10 4.96 7.70
EV/FCF (4.36) (66.83) (47.20) (38.16) (230.00) (49.14) (50.11) (33.21) (96.08) 166.74
Cash, $m
Cash, $m Operating cash flow (17) (15) (29) (22) (14) (38) (23) (50) 3 81
Capex (3) (4) (5) (20) (14) (28) (30) (40) (49) (46)
Free cash flow (19) (18) (34) (42) (27) (66) (53) (91) (46) 35
Balance, $m
Balance, $m Working capital 105 99 74 121 312 218 200 123 535 551
Total debt 32 34 35 35 33 21 35 35 646 650
Net debt (74) (68) (43) (106) (302) (218) (178) (99) 111 66
Shareholders’ equity 93 80 52 135 342 280 240 210 91 153
Returns, %
Returns, % ROA (23.75) (21.93) (40.20) (25.76) (10.72) (20.80) (25.50) (28.00) (16.60) (4.57)
ROIC (52.22) (154.41) (328.50) (114.87) (69.28) (101.17) (115.44) (70.29) (35.77) (16.42)
ROE 461.33 (34.56) (76.51) (58.19) (18.38) (32.64) (44.73) (54.86) (75.27) (36.57)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

iRhythm Holdings, Inc. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HAE Haemonetics Corporation $5.5B 57.7× 18.0× +5.60% (above 0%: growing) +2.86% (above 0%: growing) +220.38% (above 0%: growing) 59.76% 16.93% Compare
LIVN LivaNova PLC $4.3B 22.5× 26.0× +10.80% (above 0%: growing) +296.00% (above 0%: growing) −26.66% (below 0%: shrinking) 70.07% 12.67% Compare
ITGR Integer Holdings Corporation $4.3B 34.3× 27.6× −2.60% (below 0%: shrinking) −34.91% (below 0%: shrinking) +48.81% (above 0%: growing) 24.34% 7.44% Compare
IRTC iRhythm Holdings, Inc. $3.6B — (loss-making) — (loss-making) +20.08% (above 0%: growing) n/m +116.98% (above 0%: growing) 72.80% (1.13%)
NEOG Neogen Corporation $2.7B — (loss-making) — (loss-making) +6.51% (above 0%: growing) n/m +135.75% (above 0%: growing) 47.35% (0.81%) Compare
TMDX TransMedics Group, Inc. $2.7B 16.0× 34.1× +20.70% (above 0%: growing) −59.22% (below 0%: shrinking) −87.62% (below 0%: shrinking) 59.59% 12.50% Compare
UFPT UFP Technologies, Inc. $2.3B 31.2× 23.6× +15.07% (above 0%: growing) +20.63% (above 0%: growing) −35.77% (below 0%: shrinking) 29.27% 16.15% Compare
BFLY Butterfly Network, Inc. $2.1B — (loss-making) — (loss-making) +39.47% (above 0%: growing) n/m −113.85% (below 0%: shrinking) 71.41% (41.90%) Compare
AXGN AxoGen, Inc. $2.1B — (loss-making) — (loss-making) +23.06% (above 0%: growing) n/m −17.36% (below 0%: shrinking) 72.67% (3.09%) Compare
Median of peers $2.7B 31.2× 26.0× +12.94% +2.86% −22.01% 59.68% 9.97%

All 149 Medical Devices stocks →

iRhythm Holdings, Inc. (IRTC) key facts

  • Concern: iRhythm Holdings, Inc. reported a net loss of $44.6 million, or a loss of $1.39 per share, for fiscal 2025.
  • Strength: iRhythm Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $747.1 million, up 26.2% from fiscal 2024.
  • iRhythm Holdings, Inc. (IRTC) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, IRTC traded at $108.66, a market capitalization of $3.6 billion.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 4.3× sales.
  • Return on equity was −36.6% and debt-to-equity 3.50.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 4.02 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

iRhythm Holdings, Inc. (IRTC) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/IRTC · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com